Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing hidradenitis suppurativa severity and pain, especially in patients with obesity.

Panelists discuss the critical importance of early biologic therapy initiation in hidradenitis suppurativa to prevent irreversible tissue damage, reduce disease burden, and overcome socioeconomic and ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Study Overview: Incyte Corporation is conducting a Phase ...

Hidradenitis suppurativa patients face higher depression and anxiety risks, but biologic treatments may reduce these mental ...

The biopharma’s campaign for the treatment, which received FDA approval late last year to treat HS, aims to help patients get back to daily activities.

Explore how hidradenitis suppurativa is linked to increased rates of depression and anxiety, with no clear connection to ...

Hidradenitis suppurativa is associated with a higher risk for new-onset depression and anxiety, which may occur despite treatment, according to a Danish population-based cohort study.

Hidradenitis suppurativa generally causes inflamed, discolored, swollen bumps that can fill with pus and break open. Sometimes, the condition can also cause scarring and tunneling under your skin.

Finally, it’s also important to pay attention to your mental health when you have hidradenitis suppurativa; people with HS have a higher risk of depression, anxiety, and low self-esteem.